Granite Point Capital Management, L.P. Argenx Se Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$98.85 - $134.59 $1.58 Million - $2.15 Million	-16,000 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$63.81 - $109.82 $574,290 - $988,379	-9,000 Reduced 36.0%	16,000 $1.56 Million
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $1.89 Million - $2.42 Million	25,000 New	25,000 $1.89 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.